Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ES-derived NPC transplantation in Parkinson's Disease
NCT03119636Phase 2Unknown
- Sponsor
- Chinese Academy of Sciences
- Start
- May 2017
- Primary completion
- Nov 2018
- Countries
- 1
01
Overview
Phase 2, open-label trial in Parkinson's disease (PD) (3 arms), sponsored by Chinese Academy of Sciences. Primary endpoint: Treatment-Emergent Adverse Events at 6 months. Status: unknown.
02
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT03119636.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03119636.